TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02658721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Intravenous 4 mg ondansetron was administered for nausea and vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Intravenous 4 mg ondansetron was administered for nausea and vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Intravenous 4 mg ondansetron was administered for nausea and vomiting.
Study: NCT02697721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Powerful Tools for Caregivers
Description: Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Control with delayed intervention
Description: Control with delayed intervention
Study: NCT02886988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.1mlof normal saline will be injected with a 30G needle.
Study: NCT00666120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil LIPIL with iron
Description: cow's milk based infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Good Start Supreme with DHA and ARA
Description: partially hydrolzed cow's milk protein
Study: NCT00866216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.
Study: NCT01841840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Frequency Passive Vibration
Description: 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Frequency Pasive Vibration
Description: 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
Study: NCT04163666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapeutic exercise
Description: The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
Study: NCT00825474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: operation;TACE plus PEI
Description: Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
Study: NCT04937075

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02651558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - CHEST
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - CHEST & FINGER
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: OBPM 2015-MD-0022 - FINGER
Description: At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded.
Study: NCT00917254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: injection
Study: NCT04488653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin®
Description: French Maritime Pine Bark Extract - 100mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT02359435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy
Description: pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
Study: NCT00707863

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: 10 mg of Escitalopram by mouth once a day for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: 10 mg of Escitalopram by mouth once a day for 8 weeks
Study: NCT02321540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily.
Study: NCT02797483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Blue
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Green
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Fat Red
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
Study: NCT00051311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Recipients will receive donor stem cells 3 days after conditioning therapy is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study: NCT03898843

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rectal swab sampling
Description: All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
Study: NCT00555685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 7,5% (Hypertonic Saline Solution)
Description: Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
Study: NCT00051311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study: NCT02661451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Heart Failure Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optimal Heart Failure Therapy
Study: NCT03174197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02561416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.

Intervention type: DRUG
Group type: OTHER
Intervention: TAU
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
Study: NCT03588767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 + anabolic substance
Description: Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Vitamin D3 + anabolic substance
Description: Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
Study: NCT03123939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
Study: NCT02847936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl plus suture
Description: episiotomy with triclosan-coated sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl suture
Description: episiotomy with non antibacterial coated suture
Study: NCT03645837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression clamp release
Description: Standard compression clamp is used and will be released at different times according to randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression clamp release
Description: Standard compression clamp is used and will be released at different times according to randomization
Study: NCT00084864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: No intervention before surgery
Study: NCT04628208

Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 v2 System
Description: A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 v2 System
Description: A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
Study: NCT03132311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccination (17 DD Biomanguinhos)
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccination (17 DD Biomanguinhos)
Description: One intramuscular injection
Study: NCT00051311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study: NCT02440555

Intervention type: OTHER
Intervention: fulfill the self-administered questionnaire
Description: Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
Study: NCT00051311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Apheresis
Description: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
Study: NCT02286661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Casting (long arm)
Description: Casting using plaster of paris after closed reduction of distal radius fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Casting (short arm)
Study: NCT02295475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT02919020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Description: Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: resistance exercise to strengthen lower limbs
Study: NCT02944045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline serum
Study: NCT01050218

Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Study: NCT01852370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 negative allogeneic hematopoietic stem cells
Description: Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
Study: NCT04602689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
Study: NCT01259687

Intervention type: DEVICE
Intervention: Non-invasive cardiac output monitoring
Description: During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
Study: NCT06161883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soffritto
Description: The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soffritto
Description: The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Study: NCT02320253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Person Group (IP)
Description: The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Conference Call Group (TCC)
Description: The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Description: Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
Study: NCT03022266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Mobile Phone App
Description: Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
Study: NCT02485353

Intervention type: DRUG
Group type: OTHER
Intervention: Vosaroxin and Cytarabine
Study: NCT01822158

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal Delivery Debrief Checklist
Description: Participating team members will utilize Vaginal Delivery Debrief checklist
Study: NCT00451698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyanotic erythropoietin
Description: Single dose IV push

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acyanotic placebo
Description: Single dose IV push